J. Burisch, T. Jess, M. Martinato, and P. L. Lakatos, The burden of inflammatory bowel disease in Europe, Journal of Crohn's and Colitis, vol.7, issue.4, pp.322-337, 2013.
DOI : 10.1016/j.crohns.2013.01.010

N. A. Molodecky, Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012.
DOI : 10.1053/j.gastro.2011.10.001

E. I. Benchimol, Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends, Inflammatory Bowel Diseases, vol.17, issue.1, pp.423-439, 2011.
DOI : 10.1002/ibd.21349

S. C. Ng, Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study, Gastroenterology, vol.145, issue.1, pp.158-165, 2013.
DOI : 10.1053/j.gastro.2013.04.007

J. Burisch and P. Munkholm, The epidemiology of inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.20, issue.8, pp.942-951, 2015.
DOI : 10.3109/00365521.2013.865259

I. Vind, Increasing Incidences of Inflammatory Bowel Disease and Decreasing Surgery Rates in Copenhagen City and County, 2003-2005: A Population-Based Study from the Danish Crohn Colitis Database, The American Journal of Gastroenterology, vol.128, issue.6, pp.1274-1282, 2003.
DOI : 10.1053/j.gastro.2005.03.003

T. Jess, K. V. Winther, P. Munkholm, E. Langholz, and V. Binder, Mortality and causes of death in Crohn's disease: Follow-up of a population-based cohort in Copenhagen County, Denmark, Gastroenterology, vol.122, issue.7, pp.1808-1814, 2002.
DOI : 10.1053/gast.2002.33632

M. Bewtra, L. M. Kaiser, T. Tenhave, and J. D. Lewis, Crohn???s Disease and Ulcerative Colitis Are Associated With Elevated Standardized Mortality Ratios, Inflammatory Bowel Diseases, vol.19, issue.3
DOI : 10.1097/MIB.0b013e31827f27ae

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755276

T. Jess, M. Frisch, and J. Simonsen, Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010, Clinical Gastroenterology and Hepatology, vol.11, issue.1, pp.43-48, 2013.
DOI : 10.1016/j.cgh.2012.09.026

F. L. Wolters, Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort, Gut, vol.55, issue.4, pp.510-518, 2006.
DOI : 10.1136/gut.2005.072793

M. D. Kappelman, The Prevalence and Geographic Distribution of Crohn???s Disease and Ulcerative Colitis in the United States, Clinical Gastroenterology and Hepatology, vol.5, issue.12, pp.1424-1429, 2007.
DOI : 10.1016/j.cgh.2007.07.012

J. Van-limbergen, Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease, Gastroenterology, vol.135, issue.4, pp.1114-1122, 2008.
DOI : 10.1053/j.gastro.2008.06.081

B. Pigneur, Natural history of Crohn??s disease, Inflammatory Bowel Diseases, vol.16, issue.6, pp.953-961, 2010.
DOI : 10.1002/ibd.21152

J. M. Polito, Crohn's disease: Influence of age at diagnosis on site and clinical type of disease, Gastroenterology, vol.111, issue.3, pp.580-586, 1996.
DOI : 10.1053/gast.1996.v111.pm8780560

A. M. Griffiths, Specificities of inflammatory bowel disease in childhood, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.509-523, 2004.
DOI : 10.1016/j.bpg.2004.01.002

X. Qin, Etiology of inflammatory bowel disease: A unified hypothesis, World Journal of Gastroenterology, vol.18, issue.15, pp.1708-1722, 2012.
DOI : 10.3748/wjg.v18.i15.1708

M. L. Marin, A. J. Greenstein, S. A. Geller, R. E. Gordon, and A. H. Aufses, A freeze fracture study of Crohn's disease of the terminal ileum: changes in epithelial tight junction organization, Am. J. Gastroenterol, vol.78, pp.537-547, 1983.

G. Schürmann, Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease, International Journal of Colorectal Disease, vol.14, issue.1, pp.41-46, 1999.
DOI : 10.1007/s003840050181

L. Jostins, Host???microbe interactions have shaped the genetic architecture of inflammatory bowel disease, Nature, vol.286, issue.7422, pp.119-124, 2012.
DOI : 10.1038/nature11582

V. Andersen, A. Olsen, F. Carbonnel, A. Tjønneland, and U. Vogel, Diet and risk of inflammatory bowel disease, Digestive and Liver Disease, vol.44, issue.3, pp.185-194, 2012.
DOI : 10.1016/j.dld.2011.10.001

J. P. Hugot, Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease, Nature, vol.411, issue.6837, pp.599-603, 2001.
DOI : 10.1038/35079107

B. E. Sands, From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation, Gastroenterology, vol.126, issue.6, pp.1518-1532, 2004.
DOI : 10.1053/j.gastro.2004.02.072

J. E. Lennard-jones and S. Shivananda, Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur, J. Gastroenterol. Hepatol, vol.9, pp.353-359, 1997.

R. G. Farmer, W. A. Hawk, and R. B. Turnbull, Clinical patterns in Crohn's disease: a statistical study of 615 cases, Gastroenterology, vol.68, pp.627-635, 1975.

M. Pimentel, Identification of a prodromal period in Crohn's disease but not ulcerative colitis, The American Journal of Gastroenterology, vol.24, issue.12, pp.3458-3462, 2000.
DOI : 10.1111/j.1572-0241.2000.03361.x

D. A. Schwartz, The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota, Gastroenterology, vol.122, issue.4, pp.875-880, 2002.
DOI : 10.1053/gast.2002.32362

L. A. García-rodríguez, A. Ruigómez, and J. Panés, Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease, Gastroenterology, vol.130, issue.6, pp.1588-1594, 2006.
DOI : 10.1053/j.gastro.2006.02.004

R. E. Andersson, G. Olaison, C. Tysk, and A. Ekbom, Appendectomy is followed by increased risk of Crohn's disease, Gastroenterology, vol.124, issue.1, pp.40-46, 2003.
DOI : 10.1053/gast.2003.50021

S. Vermeire, G. Van-assche, and P. Rutgeerts, C-Reactive Protein as a Marker for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.5, pp.661-665, 2004.
DOI : 10.1097/00054725-200409000-00026

D. B. Sachar, Erythrocyte Sedimentation as a Measure of Crohn??s Disease Activity, Journal of Clinical Gastroenterology, vol.12, issue.6, pp.643-646, 1990.
DOI : 10.1097/00004836-199012000-00009

D. 'incà and R. , Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease, Int. J. Colorectal Dis, vol.22, pp.429-437, 2007.

S. V. Kane, Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation, The American Journal of Gastroenterology, vol.76, issue.6, pp.1309-1314, 2003.
DOI : 10.1001/archinte.161.3.369

M. Mylonaki, L. Langmead, A. Pantes, F. Johnson, and D. S. Rampton, Enteric infection in relapse of inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, vol.16, issue.8
DOI : 10.1097/01.meg.0000131040.38607.09

G. E. Reese, Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.31, issue.10, pp.2410-2422, 2006.
DOI : 10.1097/00054725-200102000-00002

G. Coremans, The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn???s disease, Gastrointestinal Endoscopy, vol.30, issue.3, pp.167-172, 1984.
DOI : 10.1016/S0016-5107(84)72358-3

G. Van-assche, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.4, issue.1, pp.7-27, 2010.
DOI : 10.1016/j.crohns.2009.12.003

C. H. Seow, E. I. Benchimol, A. M. Griffiths, A. R. Otley, and A. H. Steinhart, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst. Rev, vol.77, issue.4 Pt 2, p.296, 2008.
DOI : 10.1002/14651858.CD000296.pub3

G. R. Greenberg, Oral Budesonide for Active Crohn's Disease, New England Journal of Medicine, vol.331, issue.13, pp.836-841, 1994.
DOI : 10.1056/NEJM199409293311303

O. O. Thomsen, A Comparison of Budesonide and Mesalamine for Active Crohn's Disease, New England Journal of Medicine, vol.339, issue.6, pp.370-374, 1998.
DOI : 10.1056/NEJM199808063390603

A. Otley and A. Steinhart, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst. Rev, vol.121, issue.2, 2005.
DOI : 10.1002/14651858.CD000296.pub2

R. W. Summers, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, vol.77, pp.847-869, 1979.

H. Malchow, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment, Gastroenterology, vol.86, pp.249-266, 1984.

A. Otley and A. Steinhart, Budesonide for induction of remission in Crohn's disease, Cochrane Database Syst. Rev, vol.121, issue.2, 2005.
DOI : 10.1002/14651858.CD000296.pub2

A. Dignass, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management, Journal of Crohn's and Colitis, vol.4, issue.1, pp.28-62, 2010.
DOI : 10.1016/j.crohns.2009.12.002

B. G. Feagan, Methotrexate for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.332, issue.5, pp.292-297, 1995.
DOI : 10.1056/NEJM199502023320503

A. A. Alfadhli, J. W. Mcdonald, and B. G. Feagan, Methotrexate for induction of remission in refractory Crohn's disease, Cochrane Database Syst. Rev, pp.345910-1002, 2003.

A. G. Fraser, Methotrexate, European Journal of Gastroenterology & Hepatology, vol.15, issue.3, pp.225-231, 2003.
DOI : 10.1097/00042737-200303000-00003

B. G. Feagan, A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators, N. Engl

M. Lémann, Methotrexate in Crohn's disease: long-term efficacy and toxicity, The American Journal of Gastroenterology, vol.19, issue.7, pp.1730-1734, 2000.
DOI : 10.1056/NEJM199609193351215

A. G. Fraser, D. Morton, D. Mcgovern, S. Travis, and D. P. Jewell, The efficacy of methotrexate for maintaining remission in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics, vol.26, issue.4, pp.693-697, 2002.
DOI : 10.1093/rheumatology/36.2.210

I. Tiede, CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes, Journal of Clinical Investigation, vol.111, issue.8, pp.1133-1145, 2003.
DOI : 10.1172/JCI16432

W. Sandborn, Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease, Cochrane Database Syst. Rev, p.545, 2000.

S. R. Targan, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N. Engl. J

F. Schnitzler, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009.
DOI : 10.1136/gut.2008.155812

J. Colombel, A. J. Watson, and M. F. Neurath, The 10 remaining mysteries of inflammatory bowel disease, Gut, vol.57, issue.4, pp.429-433, 2008.
DOI : 10.1136/gut.2007.122192

S. B. Hanauer, Human Anti???Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn???s Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, issue.2, pp.323-333, 2006.
DOI : 10.1053/j.gastro.2005.11.030

W. J. Sandborn, Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab, Annals of Internal Medicine, vol.146, issue.12, pp.829-838, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00159

S. Schreiber, A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn???s Disease, Gastroenterology, vol.129, issue.3, pp.807-818, 2005.
DOI : 10.1053/j.gastro.2005.06.064

B. G. Feagan, Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn???s disease with prior loss of response to infliximab, Alimentary Pharmacology & Therapeutics, vol.29, issue.Suppl. III, pp.541-550, 2011.
DOI : 10.1111/j.1365-2036.2010.04568.x

B. W. Behm and S. J. Bickston, Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis, Cochrane Database Syst. Rev, vol.354, issue.9, pp.757110-1002, 2009.
DOI : 10.1002/14651858.CD007571

J. Colombel, Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007.
DOI : 10.1053/j.gastro.2006.11.041

M. Allez, The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn??????s disease after failure of two other anti-TNF antibodies, Alimentary Pharmacology & Therapeutics, vol.68, issue.Suppl 4, pp.92-101, 2010.
DOI : 10.1111/j.1365-2036.2009.04130.x

R. L. West, Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.63, issue.9, pp.1122-1126, 2008.
DOI : 10.1111/j.1365-2036.2008.03828.x

S. Ben-horin, The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD, Alimentary Pharmacology & Therapeutics, vol.105, issue.6, pp.714-722, 2012.
DOI : 10.1111/j.1365-2036.2012.04997.x

C. Gagniere, Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease, Journal of Crohn's and Colitis, vol.9, issue.4, pp.349-355, 2015.
DOI : 10.1093/ecco-jcc/jju024

D. 'haens and G. , Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, The Lancet, vol.371, issue.9613, pp.660-667, 2008.
DOI : 10.1016/S0140-6736(08)60304-9

W. J. Sandborn, Certolizumab Pegol for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.228-238, 2007.
DOI : 10.1056/NEJMoa067594

M. Regueiro, Management and prevention of postoperative Crohn??s disease, Inflammatory Bowel Diseases, vol.15, issue.10, pp.1583-1590, 2009.
DOI : 10.1002/ibd.20909

J. Critch, Use of Enteral Nutrition for the Control of Intestinal Inflammation in Pediatric Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.54, issue.2, pp.298-305, 2012.
DOI : 10.1097/MPG.0b013e318235b397

F. M. Ruemmele, Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, Journal of Crohn's and Colitis, vol.8, issue.10, pp.1179-1207, 2014.
DOI : 10.1016/j.crohns.2014.04.005

R. B. Heuschkel, Enteral Nutrition in Children With Crohn's Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.31, issue.5, p.575, 2000.
DOI : 10.1097/00005176-200011000-00024

P. Dziechciarz, A. Horvath, R. Shamir, and H. Szajewska, Meta-analysis: enteral nutrition in active Crohn???s disease in children, Alimentary Pharmacology & Therapeutics, vol.24, issue.Suppl. 1, pp.795-806, 2007.
DOI : 10.1111/j.1365-2036.2007.03431.x

M. Zachos, M. Tondeur, and A. M. Griffiths, Enteral nutritional therapy for induction of remission in Crohn's disease, Cochrane Database Syst. Rev, vol.000542, 2007.

E. Buchanan, The use of exclusive enteral nutrition for induction of remission in children with Crohn???s disease demonstrates that disease phenotype does not influence clinical remission, Alimentary Pharmacology & Therapeutics, vol.101, issue.5, pp.501-507, 2009.
DOI : 10.1111/j.1365-2036.2009.04067.x

K. Teahon, M. Pearson, T. Smith, and I. Bjarnason, Alterations in Nutritional Status and Disease Activity during Treatment of Crohn's Disease with Elemental Diet, Scandinavian Journal of Gastroenterology, vol.2, issue.1, pp.54-60, 1995.
DOI : 10.1136/gut.21.4.279

O. Borrelli, Polymeric Diet Alone Versus Corticosteroids in the Treatment of Active Pediatric Crohn???s Disease: A Randomized Controlled Open-Label Trial, Clinical Gastroenterology and Hepatology, vol.4, issue.6
DOI : 10.1016/j.cgh.2006.03.010

F. L. Cameron, Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease, Alimentary Pharmacology & Therapeutics, vol.24, issue.Suppl. A, pp.622-629, 2013.
DOI : 10.1111/apt.12230

J. L. Grogan, Enteral Feeding Therapy for Newly Diagnosed Pediatric Crohn??s Disease: A Double-Blind Randomized Controlled Trial with Two Years Follow-Up??, Inflammatory Bowel Diseases, vol.18, issue.2, pp.246-253, 2012.
DOI : 10.1002/ibd.21690

J. C. Escher, Budesonide versus prednisolone for the treatment of active Crohn's disease in children, European Journal of Gastroenterology & Hepatology, vol.16, issue.1, pp.47-54, 2004.
DOI : 10.1097/00042737-200401000-00008

A. Levine, A Comparison of Budesonide and Prednisone for the Treatment of Active Pediatric Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.36, issue.2, pp.248-252, 2003.
DOI : 10.1097/00005176-200302000-00017

B. Canani and R. , Short-and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig, Liver Dis. Off. J. Ital. Soc. Gastroenterol

F. M. Ruemmele, Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, Journal of Crohn's and Colitis, vol.8, issue.10, pp.1179-1207, 2014.
DOI : 10.1016/j.crohns.2014.04.005

J. Markowitz, K. Grancher, N. Kohn, M. Lesser, and F. Daum, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology, vol.119, issue.4, pp.895-902, 2000.
DOI : 10.1053/gast.2000.18144

D. Turner, Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease, The American Journal of Gastroenterology, vol.17, issue.2, pp.2804-2812, 2007.
DOI : 10.1136/gut.48.5.591

S. Willot, A. Noble, and C. Deslandres, O08 METHOTREXATE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: AN 8 YEAR RETROSPECTIVE STUDY IN A CANADIAN PEDIATRIC IBD CENTER, Journal of Crohn's and Colitis Supplements, vol.3, issue.1, pp.2521-2526, 2011.
DOI : 10.1016/S1873-9954(09)70009-6

A. Griffiths, S. Koletzko, F. Sylvester, M. Marcon, and P. Sherman, Slow-Release 5-Aminosalicylic Acid Therapy in Children with Small Intestinal Crohn??s Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.17, issue.2, pp.186-192, 1993.
DOI : 10.1097/00005176-199308000-00010

J. Hyams, Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn???s Disease in Children, Gastroenterology, vol.132, issue.3, pp.863-873, 2007.
DOI : 10.1053/j.gastro.2006.12.003

F. M. Ruemmele, Efficacy of Infliximab in Pediatric Crohn??s Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy, Inflammatory Bowel Diseases, vol.15, issue.3, pp.388-394, 2009.
DOI : 10.1002/ibd.20788

R. Baldassano, Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease, The American Journal of Gastroenterology, vol.109, issue.4, pp.833-838, 2003.
DOI : 10.1046/j.1365-2036.1999.00024.x

J. Kierkus, The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn???s disease, European Journal of Gastroenterology & Hepatology, vol.24, issue.5, pp.495-500, 2012.
DOI : 10.1097/MEG.0b013e32835159f2

J. S. Hyams, Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children, Gastroenterology, vol.143, issue.2, pp.365-374, 2012.
DOI : 10.1053/j.gastro.2012.04.046

J. R. Rosh, Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn???s Disease, The American Journal of Gastroenterology, vol.132, issue.12, pp.3042-3049, 2009.
DOI : 10.1097/MPG.0b013e3181957a11

R. K. Russell, A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.359, issue.Suppl. A, pp.946-953, 2011.
DOI : 10.1111/j.1365-2036.2011.04603.x

URL : https://hal.archives-ouvertes.fr/hal-00616295

B. J. Druker, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr???Abl positive cells, Nature Medicine, vol.6, issue.5, pp.561-566, 1996.
DOI : 10.1038/376785a0

G. D. Demetri, Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors, New England Journal of Medicine, vol.347, issue.7, pp.472-480, 2002.
DOI : 10.1056/NEJMoa020461

Y. Lin and B. Roux, Computational Analysis of the Binding Specificity of Gleevec to Abl, c-Kit, Lck, and c-Src Tyrosine Kinases, Journal of the American Chemical Society, vol.135, issue.39, pp.14741-14753, 2013.
DOI : 10.1021/ja405939x

Y. Sakanoue, Increased Protein Tyrosine Kinase Activity of the Colonic Mucosa in Ulcerative Colitis, Scandinavian Journal of Gastroenterology, vol.287, issue.8, pp.686-690, 1992.
DOI : 10.1002/1097-0142(19910201)67:3<590::AID-CNCR2820670312>3.0.CO;2-Y

S. Cuzzocrea, The Tyrosine Kinase Inhibitor Tyrphostin AG 126 Reduces the Development of Colitis in the Rat, Laboratory Investigation, vol.45, issue.9, pp.1439-1453, 2000.
DOI : 10.1038/330662a0

S. C. Bischoff, Mast cells are an important cellular source of tumour necrosis factor alpha ??in human intestinal tissue, Gut, vol.44, issue.5, pp.643-652, 1999.
DOI : 10.1136/gut.44.5.643

N. Awano, Successful Treatment of Ulcerative Colitis Associated with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia, Internal Medicine, vol.50, issue.16, pp.1741-1745, 2011.
DOI : 10.2169/internalmedicine.50.5569

F. Magro and C. Costa, Long-standing remission of Crohn??s disease under imatinib therapy in a patient with Crohn??s disease, Inflammatory Bowel Diseases, vol.12, issue.11, pp.1087-1089, 2006.
DOI : 10.1097/01.mib.0000232468.15950.34

K. Miyachi, Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia, Clinical Rheumatology, vol.22, issue.4-5, pp.329-332, 2003.
DOI : 10.1007/s10067-003-0716-3

K. K. Eklund and H. Joensuu, Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases, Annals of Medicine, vol.35, issue.5, pp.362-367, 2003.
DOI : 10.1080/07853890310001339

B. Siroos, M. H. Harirchian, and R. Abolfazli, Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia, Multiple Sclerosis Journal, vol.19, issue.9, pp.1238-1239, 2013.
DOI : 10.1172/JCI28546.

G. Azizi, Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants, Iran. J. Allergy Asthma Immunol, vol.13, pp.198-206, 2014.

R. T. Paniagua, Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis, Journal of Clinical Investigation, vol.116, issue.10, pp.2633-2642, 2006.
DOI : 10.1172/JCI28546.

A. M. Wolf, The kinase inhibitor imatinib mesylate inhibits TNF-?? production in vitro and prevents TNF-dependent acute hepatic inflammation, Proceedings of the National Academy of Sciences, vol.107, issue.4, pp.13622-13627, 2005.
DOI : 10.1172/JCI10613

Y. Aono, Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice, American Journal of Respiratory and Critical Care Medicine, vol.171, issue.11, pp.1279-1285, 2005.
DOI : 10.1164/rccm.200404-531OC

C. E. Daniels, Imatinib mesylate inhibits the profibrogenic activity of TGF-?? and prevents bleomycin-mediated lung fibrosis, Journal of Clinical Investigation, vol.114, issue.9, pp.1308-1316, 2004.
DOI : 10.1172/JCI200419603

A. A. Berlin and N. W. Lukacs, Treatment of Cockroach Allergen Asthma Model with Imatinib Attenuates Airway Responses, American Journal of Respiratory and Critical Care Medicine, vol.171, issue.1, pp.35-39, 2005.
DOI : 10.1164/rccm.200403-385OC

J. S. Hyams, Development and validation of a pediatric Crohn's disease activity index, J. Pediatr. Gastroenterol. Nutr, vol.12, pp.439-447, 1991.

J. Y. Mary and R. Modigliani, Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)., Gut, vol.30, issue.7, pp.983-989, 1989.
DOI : 10.1136/gut.30.7.983

S. Ben-horin and Y. Chowers, Review article: loss of response to anti-TNF treatments in Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.58, issue.9, pp.987-995, 2011.
DOI : 10.1111/j.1365-2036.2011.04612.x

S. Ben-horin, U. Kopylov, and Y. Chowers, Optimizing anti-TNF treatments in inflammatory bowel disease, Autoimmunity Reviews, vol.13, issue.1, pp.24-30, 2014.
DOI : 10.1016/j.autrev.2013.06.002

Y. Suzuki, Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn??s Disease, Inflammatory Bowel Diseases, vol.21, issue.9, pp.2114-2122, 2015.
DOI : 10.1097/MIB.0000000000000475

F. Nuti, Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-?? Therapy in a Paediatric Crohn???s Disease Cohort, Journal of Crohn's and Colitis, vol.10, issue.1, pp.5-12, 2016.
DOI : 10.1093/ecco-jcc/jjv126

J. F. Colombel, Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy, The American Journal of Gastroenterology, vol.37, issue.5
DOI : 10.1097/00054725-200303000-00003

K. A. Appau, Use of Infliximab within 3??Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn???s Patients, Journal of Gastrointestinal Surgery, vol.159, issue.12
DOI : 10.1007/s11605-008-0646-0

T. Yamamoto and M. R. Keighley, Long-term outcome of total colectomy and ileostomy for Crohn disease, Scand. J. Gastroenterol, vol.34, pp.280-286, 1999.

R. Heuman, B. Boeryd, T. Bolin, and R. Sjödahl, The influence of disease at the margin of resection on the outcome of Crohn's disease, British Journal of Surgery, vol.18, issue.9, pp.519-521, 1983.
DOI : 10.1002/bjs.1800700904

A. Aratari, Early versus late surgery for ileo-caecal Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.55, issue.Suppl. 1, pp.1303-1312, 2007.
DOI : 10.1111/j.1365-2036.2007.03515.x

J. Brynskov, A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's Disease, New England Journal of Medicine, vol.321, issue.13, pp.845-850, 1989.
DOI : 10.1056/NEJM198909283211301

B. G. Feagan, Low-Dose Cyclosporine for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.330, issue.26, pp.1846-1851, 1994.
DOI : 10.1056/NEJM199406303302602

E. F. Stange, European trial of cyclosporine in chronic active Crohn's disease: A 12-month study, Gastroenterology, vol.109, issue.3, pp.774-782, 1995.
DOI : 10.1016/0016-5085(95)90384-4

C. Hermida-rodriguez, C. Perona, J. Garcia-valriberas, R. , P. Garcia et al., High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease, Hepatogastroenterology, vol.46, pp.2265-2268, 1999.

J. V. Santos, Intravenous Cyclosporine for Steroid-Refractory Attacks of Crohn??s Disease, Journal of Clinical Gastroenterology, vol.20, issue.3, pp.207-210, 1995.
DOI : 10.1097/00004836-199504000-00009

L. J. Egan, W. J. Sandborn, and W. J. Tremaine, Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine, American Journal of Gastroenterology, vol.110, issue.3
DOI : 10.1111/j.1572-0241.1998.00442.x

E. D. Ehrenpreis, S. V. Kane, L. B. Cohen, R. D. Cohen, and S. B. Hanauer, Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial, Gastroenterology, vol.117, issue.6, pp.1271-1277, 1999.
DOI : 10.1016/S0016-5085(99)70276-3

E. A. Vasiliauskas, An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease, Gastroenterology, vol.117, issue.6, pp.1278-1287, 1999.
DOI : 10.1016/S0016-5085(99)70277-5

S. Kane, L. J. Stone, and E. Ehrenpreis, Thalidomide as ???Salvage??? Therapy for Patients With Delayed Hypersensitivity Response to Infliximab, Journal of Clinical Gastroenterology, vol.35, issue.2, pp.149-150, 2002.
DOI : 10.1097/00004836-200208000-00006

S. Plamondon, S. C. Ng, and M. A. Kamm, Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies, Alimentary Pharmacology & Therapeutics, vol.7, issue.5, pp.557-567, 2007.
DOI : 10.1111/j.1365-2036.2006.03239.x

J. M. Sabate, An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.24, issue.6
DOI : 10.1007/s000110050209

M. Lazzerini, Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease, JAMA, vol.310, issue.20, pp.2164-2173, 2013.
DOI : 10.1001/jama.2013.280777

C. Högenauer, H. H. Wenzl, T. A. Hinterleitner, and W. Petritsch, Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.18, issue.4, pp.415-423, 2003.
DOI : 10.1046/j.1365-2036.2003.01662.x

K. Mcsharry, A. M. Dalzell, K. Leiper, and W. El-matary, Systematic review: the role of tacrolimus in the management of Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.43, issue.Suppl. 1, pp.1282-1294, 2011.
DOI : 10.1111/j.1365-2036.2011.04873.x

O. Ben-bassat, A. Iacono, S. P. Irwin, M. S. Silverberg, and G. R. Greenberg, Tu1327a Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience, Gastroenterology, vol.142, issue.5, p.804, 2012.
DOI : 10.1016/S0016-5085(12)63121-7

K. C. Bhol, AVX-470, Inflammatory Bowel Diseases, vol.19, issue.11, pp.2273-2281, 2013.
DOI : 10.1097/MIB.0b013e3182a11958

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894572

W. J. Sandborn, Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease, New England Journal of Medicine, vol.369, issue.8, pp.711-721, 2013.
DOI : 10.1056/NEJMoa1215739

URL : http://orbi.ulg.ac.be/request-copy/2268/160730/185990/2013-Vedolizumab%20as%20induction%20and%20maintenance%20therapy%20for%20Crohn%27s%20disease-New%20Engl-PostPE.pdf

B. E. Sands, Effects of Vedolizumab Induction Therapy for Patients With Crohn???s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.
DOI : 10.1053/j.gastro.2014.05.008

W. J. Sandborn, Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease, New England Journal of Medicine, vol.367, issue.16, pp.1519-1528, 2012.
DOI : 10.1056/NEJMoa1203572

G. Monteleone, Abstract Presentation, 2014.

F. Guilhot, Indications for Imatinib Mesylate Therapy and Clinical Management, The Oncologist, vol.9, issue.3, pp.271-281, 2004.
DOI : 10.1634/theoncologist.9-3-271

B. J. Druker, Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.355, issue.23, pp.2408-2417, 2006.
DOI : 10.1056/NEJMoa062867

T. B. Sneed, The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase, Cancer, vol.99, issue.1, pp.116-121, 2004.
DOI : 10.1002/cncr.11863

G. N. Mattiuzzi, Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate, Clin. Cancer Res. Off. J. Am

S. Lakhani, L. Davidson, D. A. Priebat, and A. H. Sherker, Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy, Hepatology International, vol.47, issue.1, pp.498-499, 2008.
DOI : 10.1007/s12072-008-9099-5

J. M. Daniels, A. Vonk-noordegraaf, J. J. Janssen, P. E. Postmus, and R. Van-altena, Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia, European Respiratory Journal, vol.33, issue.3, pp.670-672, 2009.
DOI : 10.1183/09031936.00025408